SHR8735-303: A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Condition: Chemotherapy Induced Thrombocytopenia

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Full Title
Protocol SHR8735-303: A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia

Study Treatment
Hetrombopag olamine is an oral medication that helps your body make more platelets by activating the receptor that triggers platelet production, which can help prevent low platelets during chemotherapy.

Eligibility/Info
Participants must be recieving treatment with a gemcitabine or platinum containing treatment regimen and be experiencing a delay in chemotherapy due to a lowered platelet count. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage